Evaluation of a urinary test to assess vitamin B12 status in older people

Urinary MMA revisited: a functional biomarker of B12 status applicable to large scale surveys. Part 2: The Intervention Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN92541398

Enrollment

100

Registered

2010-07-14

Start date

2010-01-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

public health/nutrition particularly in older people

Interventions

Capsules containing 0µg, 10µg, 100µg and 500µg Vitamin B12. One daily for 8 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Men and women (aged 65 to 85) 2. Healthy 3. Poor vitamin B12 status (plasma B12 1.5 µmol/mmol creatinine)

Exclusion criteria

Exclusion criteria: 1. Severe cognitive impairment 2. Gastric or ileal surgery 3. Regular vitamin B12 injections

Design outcomes

Primary

Measure	Time frame
1. Urinary MMA, assessed at baseline (week 0), 2, 4, 6 and 8 weeks 2, Plasma B12, assessed at baseline and 8 weeks	—

Secondary

Measure	Time frame
1. Serum holotranscobalamin 2. Plasma total folate 3. Plasma homocysteine 4. Plasma pepsinogen 5. Plasma MMA All secondary outcomes will be assessed at baseline and 8 weeks.	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026